The effects of a cognition enhancer (CILTEP) on a cognitive test battery and EEG in middle-aged and old volunteers

Gepubliceerd: 19-04-2017 Laatst bijgewerkt: 15-05-2024

- CILTEP can improve cognition in healthy volunteers, specifically memory - The effects of CILTEP will be discernable in the ERP components measured: the P50, P300, N400, and P600 amplitudes are expected to be enlarged by CILTEP

Ethische beoordeling	Positief advies
Status	Werving gestopt
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON21957

Bron
NTR

Verkorte titel
CILTEP and cognition

Aandoening

Long-term memory

Ondersteuning

Primaire sponsor: Maastricht University, Department of Neuropsychology & Psychopharmacology
Overige ondersteuning: N/A

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

To establish the effects of CILTEP on cognition, especially memory. The main cognitive tests that will be used are the verbal learning task (VLT), in which participants need to memorize words that are presented on a screen, and the spatial pattern separation test, using photographs to assess episodic memory.

Toelichting onderzoek

Achtergrond van het onderzoek

N/A

Doel van het onderzoek

- CILTEP can improve cognition in healthy volunteers, specifically memory

- The effects of CILTEP will be discernable in the ERP components measured: the P50, P300, N400, and P600 amplitudes are expected to be enlarged by CILTEP

Onderzoeksopzet

N/A

Onderzoeksproduct en/of interventie

Volunteers will be tested on 2 separate days and will be administered either CILTEP or a placebo. Before inclusion, they will undergo a memory and a medical screening The order of treatment will be randomized.

Contactpersonen

Publiek

Faculty of Psychology
Dept. of Neuropsychology and Psychopharmacology
PO Box 616

Anke Sambeth
Maastricht 6200 MD
The Netherlands
0031-(0)43-3881757

Wetenschappelijk

Faculty of Psychology
Dept. of Neuropsychology and Psychopharmacology
PO Box 616

Anke Sambeth
Maastricht 6200 MD
The Netherlands
0031-(0)43-3881757

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Male or female;

2. 30 to 40 or 60 to 75 years of age;

3. healthy (i.e. absence of all exclusion criteria);

4. body mass index between 18.5 and 30;

5. Verbal Learning Test screening score within the -1 and +1 standard deviation;

6. willingness to sign an informed consent.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. history of cardiac, hepatic, renal, pulmonary, neurological, gastrointestinal, haematological, or psychiatric ilness or a first-degree relative with a psychiatric disorder or a history with a psychiatric disorder;

2. excessive drinking (> 20 glasses of alcohol containing beverages a week);

3. pregnancy or lactation;

4. use of use of psychoactive medication or centrally acting beta blockers;

5. use of recreational drugs from 2 weeks before the experiment until the end of the study;

6. systolic blood pressure above 160 mmHg;

7. phenylketonuria;

8. any sensory or motor deficits which could reasonably be expected to affect test performance;

9. use of steroids or Sudafed (pseudoephedrine)

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Cross-over
Toewijzing:	Gerandomiseerd
Blindering:	Dubbelblind
Controle:	Placebo

Deelname

Nederland

Status:	Werving gestopt
(Verwachte) startdatum:	01-06-2017
Aantal proefpersonen:	120
Type:	Werkelijke startdatum

Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)

Wordt de data na het onderzoek gedeeld: Nee

Ethische beoordeling

Positief advies

Datum:	19-04-2017
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 47611
Bron: ToetsingOnline
Titel:

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL6001
NTR-old	NTR6400
CCMO	NL60999.068.17
OMON	NL-OMON47611

Resultaten

Samenvatting resultaten
Pending